Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057382
Status:
TERMINATED
Last Update Posted:
2005-06-24
First Post:
2003-03-31
Brief Title:
T138067 Versus Doxorubicin in Chemotherapy-Naive Unresectable Hepatocellular Carcinoma Patients
Sponsor:
Tularik
Organization:
Tularik
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2004-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an international multicenter randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma liver cancer Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer A total of 750 subjects will be enrolled in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None